

Amgen Inc. (AMGN)

Healthcare / Drug Manufacturers - General · NASDAQ Global Select

Generated: 2026-Oct-18 · Market data through: 2026-10-16

LAST CLOSE \$432.49 2026-10-16	MARKET CAP \$233.8B VOLUME 2.6M	52-WK HIGH \$447.03 52-WK LOW \$288.00	TRAILING PE 26.7 P/S 6.13	GROSS MARGIN 72.7% NET MARGIN 22.9%	ROE 89% ROIC 14%	PIOTROSKI 8/9 ALTMAN Z 2.3	1-YR RETURN +50.3% 5-YR RETURN +163.0%
---	--	---	--	--	---	---	---

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datas Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

SECTOR Healthcare INDUSTRY Drug Manufacturers - General EXCHANGE NASDAQ MARKET CAP \$233.8B EMPLOYEES 31,500 (SEC-filed) CEO Robert A. Bradway
IPO 1983-06-17 COUNTRY US
One Amgen Center Drive, Thousand Oaks, CA 91320-1799 · Tel 805 447 1000 · [amgen.com](https://www.amgen.com)

1 INSIDERSTREET SCORE

INSIDERSTREET SCORE

67 / 100

Street mean \$404.64 (25 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNAL


ROUTINE SELLING — LOW SIGNAL

\$12M sold / 6 mo, zero open-market buys

2 PRICE AND VOLUME

adjusted close, prod data layer

1 Year vs S&P 500 · AMGN +50.3% · S&P 500 +15.9% · spread +34.4pp



7 Years vs S&P 500 · AMGN +163.0% · S&P 500 +189.9% · spread -26.8pp



Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

3 INSIDERSTREET SCORE

live IS factor model

INSIDERSTREET
SCORE

67

OF 100

Score Breakdown


Profitability	88/100
Growth	74/100
Momentum	91/100
Quality	69/100
Earnings Quality	67/100
Balance Sheet	41/100
Value	43/100
Risk (safety)	50/100
Overall	67.3/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is **not** the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

SYMBOL	IS SCORE
AZN	71
GILD	44
NVS	65
PFE	46
MRK	49
BMY	68
AMGN	67

IS Score Trend — quarterly



4 TWO READINGS

business vs price

BUSINESS QUALITY

67 / 100

IS Score 67.3 / 100 · +0.0 from peak of 67

Quarter	Business Quality
23 Q1	57
23 Q2	60
23 Q3	55
23 Q4	45
24 Q1	40
24 Q2	38
24 Q3	45
24 Q4	58
25 Q1	59
25 Q2	58
25 Q3	60
25 Q4	62
26 Q1	67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURE

BULLISH

Technical Score 92 / 100 · Power +83 · 22 of 22 indicator votes bullish

Date	Price Structure
07-23	105%
08-13	105%
09-03	105%
09-13	13%
09-25	80%
10-05	80%
10-16	105%

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 67 and price structure at 92 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

5 WHAT WOULD CHANGE OUR MIND

falsifiable - check us next quarter

TRIGGER	WHERE IT STANDS NOW	WHAT IT WOULD MEAN
IS Score reaches 75 and holds two consecutive quarters	now 67.3	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 61 → 63 → 65 → 67	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 3,172 → now 3,172	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.


6 SMART MONEY CONFLUENCE EDGE · disclosure sources

SITE CONVERGENCE SCORE 3 of 4 top 4% of 29,420 symbols	SOURCES ALIGNED — of 3 independent disclosures	CONGRESS (180D) 6 buys 2026-09-22	INSIDER BUYS (180D) 0 none disclosed
ETF FUNDS (30D) 1787 up / 1434 down net +353 funds	INSTITUTIONS ADDED (13F) 19 managers opening or increasing		

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

7 INSTITUTIONAL OWNERSHIP - 12-QUARTER TREND 13F · filed 45 days after quarter end

Institutions holding — 12 quarters



Peak 3,172 · latest 3,172 (+0 from peak).

QUARTER	HOLDERS	13F SHARES	VALUE	REPORTED OWN%
2026 Q2	3,172	462.0M	\$164.3B	85.6%
2026 Q1	3,153	435.2M	\$151.5B	80.6%
2025 Q4	3,103	444.0M	\$143.5B	82.2%
2025 Q3	2,827	423.1M	\$118.1B	78.3%
2025 Q2	2,866	432.8M	\$119.6B	80.2%
2025 Q1	2,939	429.0M	\$132.1B	79.4%
2024 Q4	2,868	418.5M	\$107.5B	77.5%
2024 Q3	2,831	410.1M	\$129.5B	75.9%
2024 Q2	2,796	413.4M	\$127.2B	76.5%
2024 Q1	2,726	409.9M	\$114.7B	75.9%
2023 Q4	2,725	410.9M	\$116.2B	76.1%
2023 Q3	2,512	406.4M	\$107.5B	75.2%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


8 INSIDER ACTIVITY live Form 4 data

INSIDER	ROLE	DATE	TYPE	SHARES	VALUE	POST-TXN OWNED
Dittrich Thomas J.W.	EVP & CFO	2026-09-04	—	17,201	\$7.07M	0
Khosla Rachna	SVP, Business Development	2026-08-13	EXERCISE	1,252	\$0.20M	7,656
Khosla Rachna	SVP, Business Development	2026-08-13	SELL	1,252	\$0.52M	6,404
Khosla Rachna	SVP, Business Development	2026-08-13	EXERCISE	1,252	\$0.20M	0
Khosla Rachna	SVP, Business Development	2026-08-11	SELL	2,000	\$0.83M	6,404
Busch Matthew C.	VP, Finance & CAO	2026-08-07	A-Award	730	—	5,080
Ishrak Omar	director	2026-08-07	A-Award	85	—	7,486
Holley Charles M	director	2026-08-07	A-Award	103	—	12,990

9 SELL DECOMPOSITION — ROUTINE VS. DISCRETIONARY EDGE

6-MO DECOMPOSITION (FORM 4)	TXNS	SHARES	VALUE	SIGNAL WEIGHT
S — Open-market sales	6	31,601	\$12.1M	Counted
M — Exercises (paired A/D)	8	182,686	\$29.4M	None — mechanics
F — Tax withholding	53	161,838	\$59.5M	None — compensation
P — Open-market purchases	0	0	\$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)



Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SIGNAL Routine Selling — Low Signal	OPEN-MARKET SELLS \$12.1M 6 txns / 6 mo	OPEN-MARKET BUYS \$0.0M 0 txns / 6 mo	CLUSTER None active 3+ insiders / 21 days
--	--	--	--

10 FORM 144 PLANNED-SALE PIPELINE live EDGAR data

FILED	FILER	SHARES REGISTERED	EST. PROCEEDS
2026-08-13	Khosla Rachna	1,252	\$0.5M
2026-08-11	Khosla Rachna	2,000	\$0.8M
2026-08-06	Grygiel Nancy A.	2,970	\$1.2M
2026-08-06	Derek Miller	3,890	\$1.6M
Trailing 12 mo	11 filings	80,719	\$31M

11 13D / 13G STAKES COND

FILED	FORM	REPORTING PERSON	% OF CLASS	SHARES
2026-05-14	SCHEDULE 13G	Capital World Investors	5.50%	29.6M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-09-08	SCHEDULE 13G/A	The Vanguard Group	10.00%	53.9M sh
2025-04-17	SCHEDULE 13G/A	BlackRock, Inc.	7.60%	40.8M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

12 CONGRESSIONAL TRADING					EDGE · STOCK Act
MEMBER	CHAMBER	TRADE	SIZE BAND	TRADED	DISCLOSED
David Taylor	House	BUY	\$1,001 - \$15,000	2026-09-22	2026-10-02
Ro Khanna	House	BUY	\$1,001 - \$15,000	2026-09-04	2026-10-09
David Taylor	House	SELL	\$1,001 - \$15,000	2026-08-26	2026-09-07
Sheldon Whitehouse	Senate	SELL	\$1,001 - \$15,000	2026-08-12	2026-09-02
Sheldon Whitehouse	Senate	SELL	\$1,001 - \$15,000	2026-08-12	2026-09-02
Sheldon Whitehouse	Senate	SELL	\$1,001 - \$15,000	2026-08-12	2026-09-01
HOUSE 12-MO 33 trades 16 purchases		SENATE 12-MO 13 trades 0 purchases		COVERAGE STOCK Act filings 30-45 day disclosure lag	

13 INSTITUTIONAL OWNERSHIP & 13F FLOW				live 13F data
13F FILERS (LAST COMPLETE Q) 3,153	13F SHARES 435M 80.6% of shares out	NEW / CLOSED 226 / 126 positions, QoQ	INCREASED / REDUCED 1,216 / 1,251 positions, QoQ	
PUT/CALL (13F) 0.89 option positions	FREE FLOAT 99.7% 539M sh			

2.8 · Largest Reporting 13F Managers


MANAGER	SHARES	VALUE
Assenagon Asset Management S.A.	1.1M	\$455M
Smead Capital Management, Inc.	586,504	\$247M
Forum Financial Management, Lp	347,857	\$147M
Wealth Enhancement Advisory Servic	340,323	\$109M
Ferguson Wellman Capital Managemen	243,747	\$103M
Sarasin & Partners Llp	180,232	\$76M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.


2.9 · Top ETF & Fund Ownership

FUND	WEIGHT	POSITION
VITSX	0.3%	\$7.2B
VTSAX	0.3%	\$7.2B
VSMPX	0.3%	\$7.2B
VTI	0.3%	\$7.2B
VFINX	0.3%	\$6.0B
VFFSX	0.3%	\$6.0B

13F Filers Holding AMGN — quarterly



Institutional Put/Call — quarterly




THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

14 SHORT VOLUME — DAILY, 60 SESSIONS


EDGE · live FINRA feed



LATEST SESSION 43.8% 2026-10-15	20-DAY AVG 54.2% 50-day 52.2%	TREND Rising 20d vs 50d	BY MARKET CENTER Q: 43% · N: 64% · B: 41% latest session
--	--	--------------------------------------	---

15 DARK POOL ACTIVITY

EDGE · live ATS data




Where AMGN Trades in the Dark

ATS VENUE (4-WK)	SHARES	AVG TRADE
Incr Intelligent Cross Llc	2.9M	32 sh
Ubsa Ubs Ats	2.6M	37 sh
Sgmt Sigma X2	1.5M	27 sh
Ebxl Level Ats	1.5M	20 sh
Mlix Instinct X	1.4M	42 sh
Bids Bids Ats	1.3M	345 sh

16 REVENUE FLOW — FY2025

live segmentation + income data



Where a dollar of Amgen Inc. revenue goes. All values FY2025 filings, live.

17 GEOGRAPHIC REVENUE

live segmentation

REGION	REVENUE	SHARE
UNITED STATES	\$26.4B	72%
Non-US	\$10.3B	28%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

18 MOAT & COMPETITIVE POSITION


LIVE MODEL · 58/100 NARROW

Moat score 58/100 — Narrow; primary source Efficient Scale.



AMGN (live moat model) Peer median: AZN · GILD · NVS · PFE · MRK
Component scores from the live moat model. Peer median illustrative.

3.8 · Employees (SEC filings)





19 CORPORATE INFORMATION — KEY OFFICERS

31,500 employees

OFFICER	TITLE
Robert A. Bradway	Chairman & CEO
James E. Bradner	EVP of Research & Development, Artificial Intelligence and Data
Peter H. Griffith	Executive Vice President
Thomas J. W. Dittrich	Executive Vice President & Chief Financial Officer

20 REVENUE & EPS — HISTORY AND ESTIMATES

live consensus



Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.


NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

21 ESTIMATE VS. ACTUAL & SURPRISES

live data

Quarterly EPS — Actual vs. Consensus

BEATS (>2%) 6 of 6 recent quarters	AVG SURPRISE +12.1%	NEXT REPORT 2026-11-03	INCOME QUALITY 1.43 OCF + net income
---	-------------------------------	----------------------------------	---



22 REPORTED VS. CONSENSUS — FULL HISTORY

0 quarters · live data


BEAT RATE —% 0 of 0 quarters	CURRENT STREAK 0 longest 0	AVG EPS SURPRISE —% median —%	SURPRISE TREND — last 4 vs prior 4
---	---	--	---

PERIOD	EPS EST.	EPS ACTUAL	EPS SURPRISE	REV EST. (\$M)	REV ACTUAL (\$M)	REV SURPRISE
--------	----------	------------	--------------	----------------	------------------	--------------


Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

INCOME TRENDS — 5 YEAR

live financials




Profit Margins (%)



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked



Live segmentation data.

YoY Growth Heatmap — Income Lines

YOY GROWTH	FY21	FY22	FY23	FY24	FY25
Revenue	+2.2%	+1.3%	+7.1%	+18.6%	+9.9%
Gross profit	+1.3%	+2.0%	-0.7%	+4.0%	+26.5%
Operating income	-16.4%	+25.2%	-17.4%	-8.1%	+47.1%
Net income	-18.9%	+11.2%	+2.5%	-39.1%	+88.5%


23 INCOME STATEMENT — FULL

live financials

\$B · FY ENDS	FY21	FY22	FY23	FY24	FY25	TREND
Revenue	26.0	26.3	28.2	33.4	36.7	
Cost of revenue	6.5	6.4	8.4	12.9	10.7	
Gross profit	19.5	19.9	19.8	20.6	26.0	
R&D expense	6.3	4.4	4.8	6.0	7.0	
SG&A expense	5.4	5.4	6.2	7.1	7.1	
Operating income	7.6	9.6	7.9	7.3	10.7	
EBITDA	11.3	12.2	14.8	13.4	15.8	
D&A	3.4	3.4	4.1	5.6	5.2	
Pretax income	6.7	7.3	7.9	4.6	9.0	
Income tax	0.8	0.8	1.1	0.5	1.3	
Net income	5.9	6.6	6.7	4.1	7.7	
Diluted EPS (\$)	10.28	12.11	12.49	7.56	14.23	
Diluted shares (M)	573	541	538	541	542	

CASH FLOW TRENDS


live data



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

WHERE THE CASH WENT — FY2025

cash Sankey, live data



Balance Sheet — Full


\$B	FY22	FY23	FY24	FY25	
Cash & equivalents	7.6	10.9	12.0	9.1	
ST investments	1.7	0.0	0.0	0.0	
Receivables (net)	6.4	7.9	7.5	9.6	
Total current assets	22.2	30.3	29.0	29.1	
PP&E (net)	5.4	5.9	6.5	7.9	
Goodwill + intangibles	31.6	51.3	46.3	41.0	
Total assets	65.1	97.2	91.8	90.6	
Accounts payable	1.6	1.6	1.9	20.9	
Short-term debt	1.6	1.4	3.6	4.6	
Deferred revenue	0.0	0.0	0.0	0.0	
Total current liabilities	15.7	18.4	23.1	25.5	
Long-term debt	37.4	63.2	56.5	50.0	
Total liabilities	61.5	90.9	86.0	81.9	
Shareholders' equity	3.7	6.2	5.9	8.7	

Cash Flow Statement — Full

\$B	FY22	FY23	FY24	FY25	
Net income	6.6	6.7	4.1	7.7	
D&A	3.4	4.1	5.6	5.2	
Stock-based compensation	0.4	0.4	0.5	0.0	
Working capital change	(0.7)	(0.5)	2.4	(2.0)	
Operating cash flow	9.7	8.5	11.5	10.0	
Capital expenditures	(0.9)	(1.1)	(1.1)	(1.9)	
Investing cash flow	(6.0)	(26.2)	(1.0)	(1.9)	
Buybacks	(6.4)	0.0	(0.2)	0.0	
Dividends paid	(4.2)	(4.6)	(4.8)	(5.1)	
Debt issuance / (repay)	6.6	25.7	(4.3)	(5.7)	
Financing cash flow	(4.0)	21.0	(9.4)	(10.9)	
Free cash flow	8.8	7.4	10.4	8.1	

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY



24 EXPANDED RATIO ANALYSIS (I)

live ratio engine · profitability · valuation

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
PROFITABILITY							
ROE	73.2%	126.5%	135.8%	67.6%	106.1%	89%	
ROA	9.5%	10.4%	8.3%	4.3%	8.5%	9.1%	
ROIC	21.0%	25.6%	11.3%	11.9%	16.3%	14.2%	
Gross margin	75.2%	75.7%	70.1%	61.5%	70.8%	72.7%	
Operating margin	29.4%	36.3%	28.0%	21.7%	29.1%	33.2%	
Net margin	22.7%	24.9%	23.8%	12.2%	21.0%	22.9%	
EBITDA margin	43.5%	46.2%	52.5%	40.0%	43.1%	46.2%	
FCF margin	32.3%	33.4%	26.1%	31.1%	22.0%	—	
VALUATION							
P/E	19.00	19.63	21.77	33.45	23.05	26.7	
P/B	16.71	35.13	23.46	23.28	20.53	20.0	
P/S	4.31	4.89	5.19	4.09	4.83	6.13	
P/FCF	13.36	14.64	19.87	13.16	21.94	23.0	
EV/EBITDA	12.15	13.01	13.50	13.85	13.20	15.7	
EV/Revenue	5.28	6.01	7.09	5.53	6.07	7.3	
Earnings yield	5.3%	5.1%	4.6%	3.0%	4.3%	3.74%	
FCF yield	7.5%	6.8%	5.0%	7.6%	4.6%	4.35%	

EXPANDED RATIO ANALYSIS (II)

leverage · solvency

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
LEVERAGE & SOLVENCY							
Current ratio	1.59	1.41	1.65	1.26	1.14	1.37	
Quick ratio	1.26	1.10	1.13	0.95	0.90	1.13	
Debt / equity	4.97	10.64	10.37	10.23	6.31	4.90	
Debt / assets	54.5%	59.8%	66.5%	65.4%	60.3%	59.9%	
Net debt / EBITDA	2.24	2.44	3.63	3.60	2.69	2.46	
Interest coverage	6.60	6.22	3.73	2.46	4.24	—	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EXPANDED RATIO ANALYSIS (III)							efficiency · growth · per-share · scores
RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
EFFICIENCY							
Asset turnover	0.42	0.42	0.35	0.35	0.40	0.40	
Receivables turnover	5.52	5.03	4.39	4.76	4.50	3.7	
DSO (days)	66	73	83	77	81	98	
DPO (days)	79	84	68	50	383	702	
Cash conversion cycle	213	246	327	261	-80	-386	
GROWTH (YoY)							
Revenue growth	2.2%	1.3%	7.1%	18.6%	10.0%	—	
Net income growth	-18.9%	11.2%	2.5%	-39.1%	88.5%	—	
EPS growth	-16.0%	16.5%	2.3%	-39.3%	88.2%	—	
FCF growth	-15.2%	4.8%	-16.2%	41.2%	-22.1%	—	
PER SHARE (\$)							
EPS (diluted, TTM)	10.43	12.16	12.44	7.55	14.20	16.19	
Book value / share	11.86	6.79	11.54	10.84	15.94	21.64	
Revenue / share	45.98	48.84	52.20	61.67	67.71	70.60	
FCF / share	14.83	16.30	13.63	19.18	14.92	18.84	
Cash / share	14.22	17.26	20.27	22.09	16.81	25.91	
SHAREHOLDER RETURN & SCORES							
Buyback yield	4.4%	4.9%	0.0%	0.1%	0.0%	—	
Altman Z-Score	1.66	1.61	1.38	1.25	2.18	2.3	
Piotroski F-Score	5	5	4	6	7	8/9	
Beneish M-Score	-2.43	-2.63	-2.14	-2.91	-2.47	-2.56	

25 EARNINGS QUALITY PANEL				live scores
MODEL	SCORE	ZONE	NOTE	
Piotroski F-Score	8 / 9	Strong		
Altman Z-Score	2.3	Grey zone	Grey	
Income quality	1.43	Cash-backed	OCF ÷ net income	
Beneish M-Score	-2.56	Non-manipulator	vs -2.22 threshold	

26 DUPONT & GROWTH QUALITY				live analysis engine
DUPONT DECOMPOSITION (TTM)		VALUE	GROWTH QUALITY (LIVE)	VALUE
Tax burden		0.85	Revenue stability	0.90
Interest burden		0.79	Earnings stability	0.08
Operating margin		34.0%	Earnings persistence	0.87
Asset turnover		0.42×	Revenue CAGR 3y	12.8%
Financial leverage		9.60×	EPS CAGR 3y	2.7%
= ROE		91%	FCF CAGR 3y	1.7%


THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SHAREHOLDER RETURN PROFILE live

BUYBACK YIELD 0.00%	DIVIDEND YIELD 2.30%	TOTAL SHAREHOLDER RETURN 2.68% cash yield	SBC / REVENUE 1.3% dilution pressure
-------------------------------	--------------------------------	--	---

27 MULTIPLE HISTORY — FY SNAPSHOTS + TTM live ratio engine



28 PEER COMPARISON live peer engine


COMPANY	MKT CAP	P/E	ROE	NET MARGIN	REV GROWTH	PIOTROSKI	1-YR RET
AZN	\$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
GILD	\$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
NVS	\$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
PFE	\$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
MRK	\$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
BMJ	\$122.1B	13.2	47%	25.6%	+3.1%	8/9	—
ABBV	\$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—
JNJ	\$615.9B	38.7	26%	21.9%	+8.1%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

29 ANALYST CONSENSUS & ESTIMATES live consensus

Buy

41 Analysts



MEAN TARGET (QTR) \$404.64 25 targets	TARGET VS. PRICE -6.4% last-quarter mean	NEXT REPORT 2026-11-03 street \$5.77
--	---	---

CONSENSUS ESTIMATES	REVENUE MEAN	HIGH / LOW	EPS MEAN	HIGH / LOW	# EPS EST.
FY2026	\$39.00B	\$39.55B / \$38.54B	\$23.04	\$23.32 / \$22.59	20
FY2027	\$40.45B	\$41.94B / \$39.15B	\$24.51	\$26.03 / \$22.82	19
FY2028	\$41.78B	\$47.20B / \$38.09B	\$25.90	\$29.24 / \$21.03	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

30 STREET TARGETS & THIRD-PARTY RATING

live targets + composite

Street Price Target — Trajectory

WINDOW	AVG TARGET	VS. PRICE	# TARGETS
Last Month	\$422.88	-2.2%	8
Last Quarter	\$404.64	-6.4%	25
Last Year	\$374.44	-13.4%	59
All Time	\$330.04	-23.7%	116

Rolling mean of published targets vs. last close \$432.49. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF5/5ROE5/5ROA5/5DEBT/EQ1/5P/E2/5P/B1/5

Independent quant composite as of 2026-10-16; components scored 1-5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

31 PRICE PERFORMANCE — INDEXED, 12 MO

live prices · benchmark + sector + peer set


AMGN +50.3% vs S&P 500 +15.9% — spread +34.4pp



Sector — XLV +24.2%



Peer Set — indexed to 100



All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL CHART — 6-MONTH DAILY CANDLES, INDICATORS ON

site chart, print edition



Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

MOVING AVERAGE RIBBON & TREND

site technicals-tab chart, live indicator history



MOVING AVERAGE	VALUE	DISTANCE	% DISTANCE	SIGNAL
SMA 20	\$413.39	+19.10	+4.62%	Above
SMA 50	\$414.52	+17.97	+4.34%	Above
SMA 200	\$365.67	+66.82	+18.27%	Above
EMA 9	\$421.08	+11.41	+2.71%	Above
EMA 21	\$414.51	+17.98	+4.34%	Above
EMA 50	\$406.49	+26.00	+6.40%	Above
EMA 200	\$368.77	+63.72	+17.28%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

32 TECHNICAL POWER SCORE

EDGE · site engine · 92/100 composite

TECHNICAL VERDICT

BULLISH

Power Score +83

22 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%

Momentum 25%

Volume 20%

Volatility 10%

Patterns 15%

100

100


94

100

50

BULLISH — BUT WHICH WAY IS IT TRENDING?

vote share recomputed weekly, 13 weeks




INDICATOR VOTE GRID

22 bull / 0 bear

● Price vs SMA 20	\$413.39	● Price vs SMA 50	\$414.52	● Price vs SMA 200	\$365.67
● EMA 9/21 Cross	421.1/414.5	● SMA 50/200	Golden	● ADX Direction	ADX 24
● Supertrend	\$404	● Parabolic SAR	\$398	● SMA Slope	2.340
● RSI	62.5	● Stochastic K/D	86/79	● StochRSI K/D	96/81
● Williams %R	-20	● CCI	175	● TSI vs Signal	12.5
● CMO	25.1	● ROC	7.31%	● OBV Signal	Accum
● Chaikin MF	0.090	● MFI	54	● Force Index	9M
● Elder Ray Bull	24.31				

INDICATOR GAUGES

site technicals-tab style



33 KEY LEVELS & VOLATILITY

live indicator table

LEVEL	VALUE	LEVEL	VALUE
Pivot / R1 / R2	\$436.40 / \$439.39 / \$444.74	S1 / S2	\$431.05 / \$428.06
Bollinger (20,2)	\$392.90 – \$433.88	Squeeze	Off
52-wk range	\$280.23 – \$447.03	Off 52-wk high	-3.2%
ATR (14)	\$10.66 (2.5%)	Historical vol	29.1%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

34 SEASONALITY — 20-YEAR AVERAGES

live model · win rates shown

+0.6%
Jan
55%

-1.2%
Feb
35%

+0.0%
Mar
57%

+0.5%
Apr
45%

-0.0%
May
50%

+1.6%
Jun
60%

+5.8%
Jul
80%

+0.4%
Aug
55%

+0.2%
Sep
50%

+1.1%
Oct
55%

+1.1%
Nov
60%

-0.2%
Dec
45%

Sample: 20 years — treat short histories as suggestive, not statistical.

35 RISK INDICATORS

computed from live price history

COMPUTED FROM LIVE WEEKLY PRICES	AMGN	S&P 500
Weekly volatility (σ , 1y)	3.90%	1.83%
Best / worst week (1y)	+8.1% / -13.6%	—
Max drawdown (5y, monthly)	-21.6%	—
1-week VaR (95%)	-4.6%	—
Beta (5y)	0.43	1.00

36 EQUITY WEATHER & MARKET REGIME

EDGE · live weather engine

AMGN EQUITY WEATHER (LIVE)

PARTLY CLOUDY · +22

Trend

Momentum

Volume

Volatility

Breadth

+41

+53

+42

-60

-30

MARKET REGIME (2026-10-16)

NEUTRAL

VIX

19.99

Normal

DOW THEORY

Confirmed

Bearish

SPY / QQQ TSI

7.2 / 4.7

trend strength

SECTOR STRENGTH

46/100

breadth average

37 NEWS SENTIMENT — WEEKLY

live Glauxie-scored feed

Average sentiment of 513 stories, weekly buckets, -1 to +1.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

Page 17 of 19 · © 2026 InsiderStreet.ai. All rights reserved.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

InsiderStreet

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

38 WEATHER - COMPANY VS INDUSTRY, SECTOR, UNIVERSE

EDGE · live weather engine · Partly Cloudy

OVERALL +22.1 +31.6 vs industry	TREND +41.2 +45.3 vs industry	MOMENTUM +53.3 +43.4 vs industry	VOLUME +42.4 +25.8 vs industry
--	--	---	---

READING	AMGN	DRUG MANUFACTURERS - GENERAL N=150	HEALTHCARE N=5,272	ALL US SYMBOLS N=70,435
Overall	+22.1	-9.5	-24.0	-20.5
Trend	+41.2	-4.1	-25.6	-21.3
Momentum	+53.3	+9.9	-28.5	-15.8
Volume	+42.4	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

39 EXECUTIVE COMPENSATION


live proxy data · FY2025

EXECUTIVE	TOTAL COMP	STRUCTURE
Robert A. Bradway Chief Executive Officer an	\$24.7M	67% equity+incentive
James E. Bradner Executive Vice President, R	\$8.6M	58% equity+incentive
Peter H. Griffith Executive Vice President a	\$8.6M	62% equity+incentive
Murdo Gordon Executive Vice President, Globa	\$8.5M	63% equity+incentive
David M. Reese Executive Vice President and	\$8.3M	62% equity+incentive

40 ESG ASSESSMENT

live disclosure-derived scores

PILLAR (LIVE DISCLOSURE SCORES)	SCORE
Environmental	65
Social	52
Governance	67
Composite ESG	61



41 8-K MATERIAL EVENTS

live EDGAR feed

FILED	8-K CONTENTS	ITEMS
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-07-31	Other Events	8.01
2026-05-20	Shareholder Vote	5.07
2026-05-19	Officer/Director Change	5.02
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-04-22	Officer/Director Change; Exhibits	5.02,9.01
2026-02-19	Entry into Material Definitive Agreement; Financial Statements and Exh	1.01,9.01
2026-02-03	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

42 METHODOLOGY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

43 DISCLOSURES

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

44 DATA PROVENANCE FOR THIS REPORT

[sources](#) · [coverage](#) · [method](#)

DATA DOMAIN	SOURCE	COVERAGE FOR THIS REPORT
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-28 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	118 rows · 1997 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-06 to 2026-09-04
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-04-17 to 2026-05-14
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.